Tandem Diabetes Care stock hits 52-week low at 15.34 USD

Tandem Diabetes Care (NASDAQ:TNDM) Inc’s stock reached a new 52-week low, hitting 15.34 USD, highlighting a challenging period for the company. According to InvestingPro data, the stock’s RSI suggests oversold territory, while the company maintains strong liquidity with a current ratio of 2.3 and revenue growth of 27.65% in the last twelve months. Over the past year, the stock has experienced a significant decline, with a 1-year change of -62.49%. This substantial drop reflects ongoing pressures and market conditions affecting the company’s performance. For deeper insights into Tandem’s financial health and future prospects, InvestingPro subscribers can access 8 additional ProTips and a comprehensive Pro Research Report, part of the analysis available for 1,400+ US stocks. As Tandem Diabetes Care navigates these difficulties, investors will be closely monitoring any strategic moves or market developments that could impact the stock’s trajectory moving forward.

In other recent news, Tandem Diabetes Care reported its Q1 2025 earnings, revealing a significant earnings per share (EPS) miss with a figure of -1.97 against a forecast of -0.6. Despite this, the company achieved strong revenue growth, reaching $234 million, which represents a 22% year-over-year increase, surpassing both Canaccord Genuity’s and consensus estimates. Canaccord Genuity responded by raising its price target for Tandem Diabetes Care to $59, maintaining a Buy rating, and highlighting the company’s robust international sales and strategic product developments. Meanwhile, Citi downgraded Tandem Diabetes Care to Sell from Neutral, citing increasing competitive pressures in the market. Analyst Joanne Wuensch expressed concerns about the company’s ability to navigate these challenges in the near term.

Additionally, Truist Securities initiated coverage of Tandem Diabetes Care with a hold rating and a $24 price target, acknowledging the company’s position in the U.S. market but noting share loss and below-peer growth. On the product development front, Tandem received FDA clearance for its SteadiSet Infusion Set, designed for use up to three days, with plans to seek approval for extended use. The company is also working on integrating its products with Abbott’s Libre 3 Plus and pursuing CE Mark certification for its Mobi product, expected to launch in international markets in the second half of 2025. These developments reflect Tandem Diabetes Care’s ongoing efforts to enhance its market position and product offerings amidst a competitive landscape.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.